<DOC>
	<DOCNO>NCT00172159</DOCNO>
	<brief_summary>More colorectal surgeon believe surgical resection hepatic metastasis colorectal cancer chance cure patient . The five-year survival patient hepatic metastasis colorectal cancer surgical resection approximately 30 % . However , hepatic metastasis colorectal cancer inoperable . With progress chemotherapy , example , combination 5-Fu , leucovorin , oxaliplatin , surgeon advocate approximately 20 % inoperable liver metastasis convert operable case , thus provide long-term survival patient . In study , make phase Ⅱ clinical trial regard use Folfox-4 regimen neo-adjuvant treatment inoperable hepatic metastasis . Our aim evaluate tumor response rate regimen , rate resectability liver metastasis , progression free survival overall survival patient . In addition , difference report Western Oriental country analyze . We believe study provide new perspective regard beneficial treatment modality patient hepatic metastasis colorectal cancer .</brief_summary>
	<brief_title>Influence Neoadjuvant Therapy Resectability Hepatic Metastases From Colorectal Cancers</brief_title>
	<detailed_description>More colorectal surgeon believe surgical resection hepatic metastasis colorectal cancer chance cure patient . The five-year survival patient hepatic metastasis colorectal cancer surgical resection approximately 30 % . However , hepatic metastasis colorectal cancer inoperable . With progress chemotherapy , example , combination 5-Fu , leucovorin , oxaliplatin , surgeon advocate approximately 20 % inoperable liver metastasis convert operable case , thus provide long-term survival patient . In study , make phase Ⅱ clinical trial regard use Folfox-4 regimen neo-adjuvant treatment inoperable hepatic metastasis . Our aim evaluate tumor response rate regimen , rate resectability liver metastasis , progression free survival overall survival patient . In addition , difference report Western Oriental country analyze . We believe study provide new perspective regard beneficial treatment modality patient hepatic metastasis colorectal cancer .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1. colorectal cancer primarily nonresectable hepatic metastasis , define ( one follow ) : ( 1 ) liver metastases &gt; five ; ( 2 ) liver metastases anatomically functionally nonresectable ( e.g . insufficient functional liver tissue , liver venous infiltration , liver arterial infiltration , ….. ) 2 . No extrahepatic disease 3 . No prior chemotherapy , except adjuvant chemotherapy 4 . Primary tumor resection &gt; 1 month 5 . Signed write informed consent 6 . Male female 18 75 year age 7 . Histologically confirm adenocarcinoma colon rectum 8 . No extrahepatic disease 9 . Presence least one bidimensional indicator lesion measurable CT scan MRI irradiate area 10 . Life expectancy &gt; = 3 month 11 . Karnofsky performance status &gt; = 70 % 12 . Neutrophils &gt; = 1.5 x 109/L , platelet &gt; = 100 x 109/L , hemoglobin &gt; = 9 g/dL 13 . Bilirubin level &lt; 1.5 x ULN 14 . ASAT ALAT £ 2.5 x ULN ( &lt; = 5 x ULN liver metastasis present ) 15 Serum creatinine &lt; 1.5 x ULN 16 . Effective contraception male female patient risk conception exist 1 . Brain metastasis ( know suspect ) 2 . Concurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol 3 . Any investigational agent ( ) within 4 week prior entry 4 . Previous exposure monoclonal antibody , signal transduction inhibitor EGFRtargeting therapy 5 . Clinically relevant coronary artery disease history myocardial infarction within last 12 month 6 . Acute subacute intestinal occlusion history inflammatory bowel disease Known grade 3 4 allergic reaction component treatment 7 . Known drug abuse/ alcohol abuse 8 . Legal incapacity limit legal capacity 9 . Medical psychological condition opinion investigator would permit patient complete study sign meaningful inform consent 10 . Women pregnant breastfeed 11 . Clinically relevant peripheral neuropathy 12 . Any concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix . ( Patients previous malignancy without evidence disease &gt; = 5 year allow enter trial )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Surgery</keyword>
	<keyword>Liver metastasis</keyword>
</DOC>